大洋生物(003017.SZ)：预计2025年净利润同比上升50.6%—72.56%

Core Viewpoint - The company expects a significant increase in net profit for 2025, with projections ranging from 96 million to 110 million yuan, representing a year-on-year growth of 50.60% to 72.56% [1] Financial Performance - The net profit attributable to shareholders is projected to rise by 50.60% to 72.56% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 90 million and 104 million yuan, reflecting a growth of 47.14% to 70.02% year-on-year [1] Business Drivers - The primary drivers of this performance are the core products, potassium carbonate and veterinary raw materials, which have shown strong growth in both volume and price [1] - The increase in production and sales volume of these products has highlighted the benefits of economies of scale [1] - Changes in market supply and demand dynamics, along with rising raw material costs, have led to an increase in product sales prices compared to the previous year [1] - The combination of increased volume and price has contributed to a rise in gross profit margin, which is a key support for the company's net profit growth [1]